Teva Statement on Reaching an Agreement with the U.S. Administration
Teva Pharmaceuticals has finalized its agreement with the U.S. government to lower the cost of select medicines for American patients covered by Medicaid. Additionally, Teva will maintain a dedicated reserve of active pharmaceutical ingredients (API) in support of public health needs and invest in domestic pharmaceutical manufacturing.
Teva built its business around delivering affordable medicines and expanding access to the medicines patients need remains central to the company's mission. The agreement reflects our commitment to strengthening U.S. medicines supply and ensuring patients have access to affordable medicines today and the innovative treatments they will need tomorrow.